EFE Salud’s radio programme El Bisturí has interviewed Gloria Pascual, researcher with IRB Barcelona’s Stem Cells and Cancer Laboratory at the Institute for Research in Biomedicine (IRB Barcelona), in relation to research by Joan Massagué, Director of the Sloan Kettering Institute, co-founder of IRB Barcelona and current Chair of its External Advisory Board. The study in question describes the origin of metastasis, a process by which cells leave the primary tumour, invade vital organs and seed a new tumour. Metastasis is responsible for 90% of cancer deaths.
The main goal of the research into this field is to discover new therapeutic targets specifically against metastatic cells. The study headed by Massagué identifies the protein that mediates metastasis. “This paves the way for the development of new drugs that can be used for certain types of tumour, and especially for those that express high levels of this protein,” says Pascual.
link to: El Bisturí (minuto 01:00- 11:00)
About IRB Barcelona
Created in 2005 by the Generalitat de Catalunya (Government of Catalonia) and University of Barcelona, IRB Barcelona is a Severo Ochoa Centre of Excellence, a seal that was awarded in 2011. The institute is devoted to conducting research of excellence in biomedicine and to transferring results to clinical practice, thus improving people’s quality of life, while simultaneously promoting the training of outstanding researchers, technology transfer, and public communication of science. Its 27 laboratories and eight core facilities address basic questions in biology and are orientated to diseases such as cancer, metastasis, Alzheimer’s, diabetes, and rare conditions. IRB Barcelona is an international centre that hosts 400 employees and more than 30 nationalities. It is located in the Barcelona Science Park. IRB Barcelona is a CERCA center, and a member of the Barcelona Institute of Science and Technology (BIST).